Stem Cell 'Teething Problems' -- Pricing to Manufacturing, the European View
From Europe this morning comes a perspective on the "three obstacles" that are blocking cell therapy from the mainstream.
It is a subject, of course, that resonates in the United States and particularly in California, where the $3 billion state stem cell agency is running out of cash and needs a boost.
The article appeared on Labiotech, which bills itsel…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.